Nanjing Well Pharmaceutical Co Ltd (603351) — Cash Flow Reinvestment Rate
Nanjing Well Pharmaceutical Co Ltd (603351) has a Cash Flow Reinvestment Rate of 0.15x as of September 2025, reinvesting CN¥10.29 Million (capex CN¥10.29 Million ) from operating cash flow of CN¥69.51 Million. Explore Nanjing Well Pharmaceutical Co Ltd capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Nanjing Well Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2014–2024)
Historical reinvestment intensity for Nanjing Well Pharmaceutical Co Ltd across 10 annual periods. Also explore total assets of Nanjing Well Pharmaceutical Co Ltd for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Nanjing Well Pharmaceutical Co Ltd (2014–2024)
Year-by-year capital reinvestment analysis for Nanjing Well Pharmaceutical Co Ltd. For live market cap and broader valuation context, see 603351 stock market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.31x | CN¥69.78 Million | CN¥221.79 Million | CN¥51.46 Million | ▼ -51.7% |
| 2023 | 0.65x | CN¥78.30 Million | CN¥120.24 Million | CN¥73.07 Million | ▼ -70.3% |
| 2022 | 2.19x | CN¥238.63 Million | CN¥108.99 Million | CN¥233.90 Million | ▼ -49.1% |
| 2020 | 4.30x | CN¥401.31 Million | CN¥93.30 Million | CN¥282.44 Million | ▲ +12.3% |
| 2019 | 3.83x | CN¥496.88 Million | CN¥129.69 Million | CN¥120.62 Million | ▼ -46.1% |
| 2018 | 7.11x | CN¥453.22 Million | CN¥63.76 Million | CN¥76.95 Million | ▲ +15.2% |
| 2017 | 6.17x | CN¥439.62 Million | CN¥71.27 Million | CN¥63.35 Million | ▲ +1017.9% |
| 2016 | 0.55x | CN¥70.73 Million | CN¥128.18 Million | CN¥69.31 Million | ▼ -41.8% |
| 2015 | 0.95x | CN¥76.92 Million | CN¥81.14 Million | CN¥76.92 Million | ▼ -20.1% |
| 2014 | 1.19x | CN¥88.54 Million | CN¥74.62 Million | CN¥88.54 Million | — |